5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a potent psychedelic compound found in the secretion from the parotid glands of the Bufo alvarius toad, native to the Sonoran Desert of...
Patients with Major Depressive disorder (MDD) have been shown to achieve remission within three months following treatment with SPL026 combined with supportive therapy in Small Pharma’s...
Detailed brain imaging data from 20 healthy volunteers has revealed how DMT increased connectivity across the brain, with more communication between different areas and systems.
Small Pharma has announced results from its Phase 2a trial of its intravenous formulation of DMT – SPL026 – demonstrating improvement in depression and anxiety.
PharmaDrug Inc.
The US Food and Drug Administration (FDA) has given IND approval for a Phase 2b study of a synthetic formulation of 5-MeO-DMT – BPL-003.
Small Pharma has reported positive top-line results from its Phase 2a Trial of SPL026 in Major Depressive Disorder (MDD).
Algernon Pharmaceuticals has announced that its subsidiary, Algernon NeuroScience (AGN Neuro), has dosed the first subject in its Phase 1 clinical study of an intravenous formulation...
Biopharmaceutical company Cybin has selected generalised anxiety disorder (GAD), with or without major depressive disorder (MDD), as the target indication for its proprietary deuterated DMT molecule,...
The first patient has been dosed in Small Pharma’s Phase I study that is comparing the profiles of the company’s proprietary formulation of DMT.